AbCellera Biologics Inc (NASDAQ:ABCL) has a beta value of 0.47 and has seen 1.12 million shares traded in the recent trading session. The company, currently valued at $661.53M, closed the recent trade at $2.22 per share which meant it lost -$0.11 on the day or -4.72% during that session. The ABCL stock price is -130.63% off its 52-week high price of $5.12 and 0.9% above the 52-week low of $2.20.
The consensus among analysts is that AbCellera Biologics Inc (ABCL) is Buy stock at the moment, with a recommendation rating of 1.22. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.14.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Sporting -4.72% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ABCL stock price touched $2.22 or saw a rise of 7.88%. Year-to-date, AbCellera Biologics Inc shares have moved -24.23%, while the 5-day performance has seen it change -5.93%. Over the past 30 days, the shares of AbCellera Biologics Inc (NASDAQ:ABCL) have changed -32.52%.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 55.6% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -125.23% off the targeted high while a plunge would see the stock gain -125.23% from the levels at last check today.
AbCellera Biologics Inc (ABCL) estimates and forecasts
The company’s shares have lost -8.64% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -8.82%.
7 analysts offering their estimates for the company have set an average revenue estimate of 7.12M for the current quarter. 7 have an estimated revenue figure of 6.71M for the next ending quarter. Year-ago sales stood 9.95M and 7.32M respectively for this quarter and the next, and analysts expect sales will shrink by -28.43% for the current quarter and -8.82% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -107.74% over the past 5 years. Earnings growth for 2025 is a modest -10.53% while over the next 5 years, the company’s earnings are expected to decrease by -9.14%.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
The top two institutional holders are BAKER BROS. ADVISORS LP with over 27.53 million shares worth more than $81.48 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 9.3556% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 21.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.86 million and represent 7.4472% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Smallcap World Fund and iShares Biotechnology ETF. As of Dec 31, 2024, the former fund manager holds about 2.53% shares in the company for having 7.54 shares of worth $16.63 million while later fund manager owns 1.45 shares of worth $3.19 million as of Dec 31, 2024, which makes it owner of about 0.49% of company’s outstanding stock.
